Kissei Pharmaceutical Co., Ltd. (TYO:4547)
Japan · Delayed Price · Currency is JPY 4,650.00
+20.00 (0.43%)
Feb 13, 2026, 3:30 PM JST
Kissei Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 95,294 | 88,330 | 75,579 | 67,493 | 65,381 | 69,044 | |
Revenue Growth (YoY) | 14.28% | 16.87% | 11.98% | 3.23% | -5.30% | 9.19% |
Cost of Revenue | 49,355 | 44,265 | 38,238 | 35,118 | 34,143 | 36,321 |
Gross Profit | 45,939 | 44,065 | 37,341 | 32,375 | 31,238 | 32,723 |
Selling, General & Admin | 48,085 | 22,179 | 20,790 | 20,289 | 19,923 | 19,607 |
Research & Development | - | 12,889 | 9,474 | 10,391 | 10,363 | 9,626 |
Other Operating Expenses | - | 129 | 143 | 149 | 137 | 149 |
Operating Expenses | 48,085 | 38,291 | 33,324 | 33,518 | 32,640 | 31,217 |
Operating Income | -2,146 | 5,774 | 4,017 | -1,143 | -1,402 | 1,506 |
Interest Expense | -26 | -21 | -18 | -20 | -23 | -23 |
Interest & Investment Income | 1,639 | 1,449 | 1,318 | 1,402 | 1,586 | 1,272 |
Currency Exchange Gain (Loss) | -391 | -229 | -103 | 186 | -60 | -130 |
Other Non Operating Income (Expenses) | 45 | 29 | 35 | 57 | 280 | 131 |
EBT Excluding Unusual Items | -879 | 7,002 | 5,249 | 482 | 381 | 2,756 |
Gain (Loss) on Sale of Investments | 18,598 | 11,719 | 9,119 | 13,133 | 16,161 | 4,727 |
Gain (Loss) on Sale of Assets | -167 | -215 | 80 | 63 | -35 | -10 |
Asset Writedown | - | -2,895 | - | - | - | - |
Other Unusual Items | -280 | -2 | -1 | 1 | -1 | 3 |
Pretax Income | 17,643 | 15,609 | 14,447 | 13,679 | 16,506 | 7,476 |
Income Tax Expense | 3,364 | 3,634 | 3,159 | 3,046 | 3,475 | 2,098 |
Earnings From Continuing Operations | 14,279 | 11,975 | 11,288 | 10,633 | 13,031 | 5,378 |
Minority Interest in Earnings | -144 | -14 | -128 | -105 | -110 | -93 |
Net Income | 14,135 | 11,961 | 11,160 | 10,528 | 12,921 | 5,285 |
Net Income to Common | 14,135 | 11,961 | 11,160 | 10,528 | 12,921 | 5,285 |
Net Income Growth | 21.20% | 7.18% | 6.00% | -18.52% | 144.48% | 87.61% |
Shares Outstanding (Basic) | 42 | 44 | 45 | 46 | 46 | 47 |
Shares Outstanding (Diluted) | 42 | 44 | 45 | 46 | 46 | 47 |
Shares Change (YoY) | -4.74% | -3.62% | -1.86% | - | -1.18% | -0.11% |
EPS (Basic) | 337.35 | 274.20 | 246.58 | 228.30 | 280.19 | 113.25 |
EPS (Diluted) | 337.35 | 274.20 | 246.58 | 228.30 | 280.19 | 113.25 |
EPS Growth | 27.23% | 11.20% | 8.01% | -18.52% | 147.41% | 87.81% |
Free Cash Flow | - | 2,014 | -2,878 | -8,782 | 44 | -3,473 |
Free Cash Flow Per Share | - | 46.17 | -63.59 | -190.44 | 0.95 | -74.42 |
Dividend Per Share | 115.000 | 100.000 | 82.000 | 80.000 | 56.000 | 54.000 |
Dividend Growth | 33.72% | 21.95% | 2.50% | 42.86% | 3.70% | 3.85% |
Gross Margin | 48.21% | 49.89% | 49.41% | 47.97% | 47.78% | 47.39% |
Operating Margin | -2.25% | 6.54% | 5.32% | -1.69% | -2.14% | 2.18% |
Profit Margin | 14.83% | 13.54% | 14.77% | 15.60% | 19.76% | 7.66% |
Free Cash Flow Margin | - | 2.28% | -3.81% | -13.01% | 0.07% | -5.03% |
EBITDA | 2,740 | 10,389 | 8,271 | 2,966 | 2,328 | 4,654 |
EBITDA Margin | 2.88% | 11.76% | 10.94% | 4.40% | 3.56% | 6.74% |
D&A For EBITDA | 4,886 | 4,615 | 4,254 | 4,109 | 3,730 | 3,148 |
EBIT | -2,146 | 5,774 | 4,017 | -1,143 | -1,402 | 1,506 |
EBIT Margin | -2.25% | 6.54% | 5.32% | -1.69% | -2.14% | 2.18% |
Effective Tax Rate | 19.07% | 23.28% | 21.87% | 22.27% | 21.05% | 28.06% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.